Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
The main results reproduced, with only marginal, non-material deviations.
A 0–100 reproducibility-quality score from the per-question grades, shown as a z-score: standard deviations above (+) or below (−) the mean of comparable assessments.
▸Reproduction agent’s raw note
Described well enough for the DEG pipeline (the only code-free, in-scope part); NOT for the novel classifier (repo gone). Independent re-run on «our HPC» (SLURM «job», EXIT 0) reproduced the experimental design EXACTLY (merged 135 BC/44 normal; GSE45827 144/11; GSE10810 31/27; GSE42568 104/17) and the DEG counts to the same order of magnitude and direction with a faithful RMA->ComBat->limma pipeline (|logFC|>2 & p<0.05): merged 255 vs reported 164 (66up/189down vs 34/130); GSE45827 321 vs 350 (172up/149down vs 208/142) -> PARTIAL. The residual gap is dominated by the paper's under-specified 'unexpressed-probe removal' (paper ~10.6-11.7k genes vs our 20,824); a matched-gene-count sensitivity pulls merged toward the paper (208 vs 164; down 148 vs 130). Outputs are BIT-IDENTICAL to the prior run (sha256 deg_results.json 7ff0adc8...) -> fully deterministic, no fabrication signal: all numbers are plausible reproduction drift from documented under-specification, and sample-design matches to the individual sample. NOT attempted (out of scope): the BGWO_SA_Ens feature-selection + ensemble classifier and ALL downstream results (F1/AUC, 1404/1710 selected genes, 35 superior genes, named biomarkers, drug-target/enrichment/PPI) because the authors' GitHub repo returns 404 (repo_gone, re-verified 2026-06-22). All three GEO datasets (GSE45827/GSE10810/GSE42568, GPL570) are open, complete, and deliver exactly what the paper promises (N matches to the sample). Compute ran entirely on «our HPC» compute nodes (SLURM); a transient shared-account «infra» quota block was waited out, not worked around dishonestly.
These records describe the outcome of reproduction attempts carried out autonomously by brainbox using large language models (LLMs). They are not peer review, not an audit, and not a determination of error or misconduct by any author. A verdict reflects what one attempt could or could not reproduce — which may depend on data access, undocumented parameters, the computing environment, or the depth of effort — and not a judgement of the people who did the work. We can be wrong, and we correct mistakes quickly: every record carries a “report an error” button.
Assessment versions
Every reproduction run is kept as an immutable version — anchored to the data as it stood, with a tamper-evident chain hash. A rerun (e.g. after an author updates a deposit) adds a new version; the previous one stays on record.
-
v1 current initial assessment Score 55assessed: 2026-06-16 ⛓ 4c43924beefd
✎ I am an author of this paper
Updated or fixed a deposit, or is there an erratum? Ask us to re-run the metrics. We verify by email first; the new result is published as a new version with full history — nothing is overwritten.
Provenance — full disclosure
When this reproduction was carried out, which methodology version was used, and by whom — so the record can be audited and checked independently.
- Reproduced
- 2026-06-22
- Rubric version
- not recorded
- Assessed by
- —
- Last updated
- 2026-08-05
Provisional, curator- or AI-assessed, and independently checkable. A reproduction outcome states what one attempt could reproduce — not a judgement of the authors.
Deep full-text extraction
Model: sonnetThe study tests whether an integrative machine learning approach—merging breast cancer gene expression datasets and applying a novel hybrid metaheuristic feature selection algorithm (BGWO_SA_Ens, combining binary grey wolf optimization, simulated annealing, and an ensemble classifier)—can more accurately identify breast cancer biomarkers and drug targets than existing methods.
- ★ The BGWO_SA_Ens algorithm (hybrid BGWO + simulated annealing with an ensemble classifier objective function) selects predictive breast cancer biomarker genes with high classification performance method
- ★ Differential expression analysis of the merged dataset (GSE10810 + GSE42568) identified 164 differentially expressed genes between breast cancer and normal samples finding
- ★ Differential expression analysis of the separate GSE45827 dataset identified 350 differentially expressed genes finding
- ★ Intersecting DEGs with BGWO_SA_Ens-selected genes yields 35 'superior genes' consistently significant across both methods finding
- ★ The 35 superior genes are involved in AMPK, Adipocytokine, and PPAR signaling pathways mechanism
- ★ Protein-protein interaction network analysis of superior genes highlights subnetworks and central hub nodes finding
- ★ Drug-gene interaction analysis reveals connections between superior genes and anticancer drugs, informing precision oncology resource
- ★ This is the first study to apply a combination of hybrid metaheuristic algorithms and ensemble models to gene expression data for breast cancer biomarker discovery method
| Assay | System | Perturbation | Readout | Platform |
|---|---|---|---|---|
| Differential gene expression analysis (limma, RMA-normalized microarray) | Merged human breast tissue dataset (GSE10810 + GSE42568) | none (breast cancer vs normal tissue comparison) | Differentially expressed genes (logFC>2, p<0.05) | Affymetrix GPL570 (Human Genome U133 Plus 2.0 Array) |
| Differential gene expression analysis (limma, RMA-normalized microarray) | GSE45827 human breast tissue dataset | none (breast cancer vs normal tissue comparison) | Differentially expressed genes (logFC>2, p<0.05) | Affymetrix GPL570 (Human Genome U133 Plus 2.0 Array) |
| Feature selection via BGWO_SA_Ens (hybrid metaheuristic + ensemble classifier) | Merged breast cancer gene expression dataset (179 samples, 10,629 features) | computational feature selection (no biological perturbation) | Selected gene subset and classification performance (F1, PR-AUC, ROC-AUC) | — |
| Feature selection via BGWO_SA_Ens (hybrid metaheuristic + ensemble classifier) | GSE45827 gene expression dataset (155 samples) | computational feature selection (no biological perturbation) | Selected gene subset and classification performance (F1, PR-AUC, ROC-AUC) | — |
| Comparative feature selection (BGWO_Ens, GA_Ens, LASSO, MCFS_IFS, mRMR_IFS) | Merged dataset and GSE45827 dataset | computational feature selection | Comparative classification/selection performance vs BGWO_SA_Ens | — |
| Gene Ontology (GO) and KEGG pathway enrichment analysis | 35 superior genes (intersection of DEGs and BGWO_SA_Ens selections) | none | Enriched biological pathways/functions | — |
| Protein-protein interaction (PPI) network analysis | 35 superior genes | none | Subnetworks and central/hub nodes | — |
| Drug-gene interaction analysis | 35 superior genes | none | Associations between genes and anticancer drugs | — |
- – Differential expression analysis identified 164 DEGs in the merged dataset
- – Differential expression analysis identified 350 DEGs in the GSE45827 dataset
- – BGWO_SA_Ens selected 1404 genes from >10,000 in the merged dataset with F1=0.981, PR-AUC=0.998, ROC-AUC=0.995 F1: 0.981
- – BGWO_SA_Ens selected 1710 genes in the GSE45827 dataset with F1=0.965, PR-AUC=0.986, ROC-AUC=0.972 F1: 0.965
- – Intersection of DEGs and BGWO_SA_Ens-selected genes yielded 35 superior genes consistently significant across methods
- – Predictive genes identified include TOP2A, AKR1C3, EZH2, MMP1, EDNRB, S100B, and SPP1
- – Superior genes are involved in AMPK, Adipocytokine, and PPAR signaling pathways per enrichment analysis
- – Drug-gene interaction analysis revealed connections between superior genes and anticancer drugs
- fold_change logFC > 2 (DEG classification threshold criterion)
- pvalue p < 0.05 (DEG significance threshold)
- count 164 (DEGs identified in merged dataset)
- count 350 (DEGs identified in GSE45827 dataset)
- count 35 (superior genes at intersection of DEGs and BGWO_SA_Ens-selected genes)
- other F1=0.981, PR-AUC=0.998, ROC-AUC=0.995 (BGWO_SA_Ens classification performance on merged dataset (1404 genes selected))
- other F1=0.965, PR-AUC=0.986, ROC-AUC=0.972 (BGWO_SA_Ens classification performance on GSE45827 dataset (1710 genes selected))
- count 179 BC samples / 44 normal samples (merged dataset composition (10,629 features) from GSE10810 (58 samples) and GSE42568 (121 samples))
Statistical methods review
Model: sonnetA neutral, descriptive read of the statistical approach — what was done, and (for shared learning, not as criticism) what could also have been done.
This computational study merges two public microarray datasets (GSE10810 + GSE42568; n=223) and separately analyzes a third dataset (GSE45827; n=155) to identify breast cancer biomarkers. Differential gene expression (DGE) was performed with the limma package in R, using log-fold change >2 and p<0.05 as thresholds; batch effects were corrected with ComBat (empirical Bayes). A novel hybrid metaheuristic feature selection algorithm (BGWO_SA_Ens) was applied to both datasets, and classification performance was summarized using F1 score, PR-AUC, and ROC-AUC. Candidate biomarkers were further characterized via enrichment analysis, protein-protein interaction networks, and drug-gene interaction databases.
| Test | Applied to | n | Assumptions |
|---|---|---|---|
| limma moderated t-test (empirical Bayes linear model) | Differential gene expression: breast cancer vs normal in merged dataset and GSE45827 | 223 (merged: 179 BC + 44 normal); 155 (GSE45827: 144 BC + 11 normal) | not stated |
| ComBat empirical Bayes batch-effect correction | Integration of GSE10810 and GSE42568 prior to DGE analysis | 223 | not stated |
| Principal Component Analysis (PCA) | Visualization of batch-effect correction efficacy (prcomp in R) | 223 | na |
| Ensemble classifier with weighted voting (BGWO_SA_Ens objective function) | Feature selection and sample classification in merged dataset and GSE45827 | 223 (merged); 155 (GSE45827) | not stated |
-
The p-value threshold for DEGs is stated as <0.05 without specifying whether raw or FDR-adjusted values were used↳ Could also: Explicitly report Benjamini-Hochberg adjusted p-values (q-values) at a standard FDR threshold (e.g., q<0.05 or q<0.1), which limma computes by default — With >10,000 genes tested simultaneously, applying a multiple-testing correction and reporting it explicitly is a standard step that clarifies the expected false discovery rate among reported DEGs
-
DEG thresholds were set at |logFC|>2 combined with p<0.05↳ Could also: A |logFC|>1 (twofold change) threshold is also widely used and would capture a broader set of biologically relevant genes; alternatively, a volcano-plot-based approach with FDR<0.05 only (no logFC filter) is common — The logFC>2 cut-off (fourfold change) is stringent and may exclude moderately but consistently dysregulated genes; reporting sensitivity to threshold choice is informative
-
Machine learning classifier performance (F1, PR-AUC, ROC-AUC) is reported as point estimates without confidence intervals or cross-validation variance↳ Could also: Report mean ± SD of performance metrics across repeated k-fold cross-validation folds, or bootstrap 95% confidence intervals for each metric — With moderately sized datasets (n=155–223), single point estimates of AUC/F1 can be sensitive to the specific split; variance estimates help characterize the stability of reported performance
-
Datasets from two sources (GSE10810, GSE42568) were merged with ComBat batch correction and then analyzed as one dataset↳ Could also: A formal meta-analysis approach (e.g., combining effect sizes across studies using a random-effects model, as implemented in the metaMA or RankProd packages) would also integrate across studies while explicitly modeling inter-study heterogeneity — Meta-analysis preserves between-study variance as an estimable quantity and produces effect-size summaries with confidence intervals, which can complement or contextualize the merged-dataset approach
-
Classification model validation used a separate held-out GEO dataset (GSE45827) as an external test set↳ Could also: Nested cross-validation (inner loop for feature selection / hyperparameter tuning, outer loop for performance estimation) on the merged dataset could also provide a nearly unbiased performance estimate without requiring an external cohort — External validation on GSE45827 is a strong design choice; nested CV would additionally allow quantifying variance in feature selection stability across splits within the merged data
-
Batch effect correction was evaluated visually via PCA of the first two principal components↳ Could also: Quantitative measures such as the k-nearest-neighbor batch-effect test (kBET) or PVCA (principal variance component analysis) also assess residual batch structure after correction — Numerical batch-effect metrics complement visual PCA inspection and provide a reproducible, threshold-based confirmation that batch variance has been adequately reduced
Citation network
Where this publication sits in the reproducibility-weighted citation graph — what it is built on, and what is built on it. Citation data from OpenAlex.
Assessed papers, coloured by verdict. Click a node to open it.
- No assessed neighbours yet — the network grows as more papers are assessed.
What was reproduced
The exact results taken into scope, with each reported value next to the value our attempt produced.
Scope — pmid-38253993
Paper: Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach. BMC Bioinformatics 2024. DOI 10.1186/s12859-024-05657-1. PMCID PMC10810249.
Code availability — REPO GONE (screened 2026-06-15)
Paper's Availability statement: "All codes ... available at https://github.com/mornejd/Refining-Breast-Cancer-Biomarker-Discovery-BGWO_SA_Ens".
- GitHub page → HTTP 404.
- GitHub REST API
/repos/mornejd/Refining-...→{"message":"Not Found","status":"404"}. - User
mornejdexists but lists only ONE public repo (ICH_MHA, unrelated). - GitHub code/repo search for
BGWO_SA_EnsandRefining Breast Cancer Biomarker Discovery→ 0 results. => The authors' analysis code (the novel BGWO_SA_Ens feature-selection + ensemble classifier) is not publicly available.drop_reasoncandidaterepo_gonefor that part.
Data availability — PUBLIC (all GEO, GPL570)
- GSE10810 (58: 31 BC / 27 normal), GSE42568 (121: 104 BC / 17 normal) → MERGED training set (135 BC / 44 normal (179 total); paper: 10,629 genes after preprocessing).
- GSE45827 (155: 144 BC / 11 normal; paper: 11,731 genes) → validation set. All Affymetrix HG-U133 Plus 2.0 (GPL570). Raw CEL available as GEO supplementary.
What is IN SCOPE (reproducible from public data + described methods)
The differential-expression (DEG) pipeline is fully specified in Methods and needs no bespoke code:
- GEOquery raw CEL → RMA (background correct + quantile normalize + summarize).
- Probe→gene: drop unmapped probes, mean-collapse multi-probe genes.
- Merge GSE10810+GSE42568, batch-correct with ComBat (sva).
- limma DEG, BC vs normal; a gene is a DEG if |logFC| > 2 AND adj.p < 0.05.
- Reported counts (Table 1): merged 164 DEGs (34 up / 130 down); GSE45827 350 DEGs (208 up / 142 down). These are the comparison targets.
What is OUT OF SCOPE / NOT ATTEMPTED (and why)
- BGWO_SA_Ens feature selection + ensemble classifier (F1, PR-AUC, ROC-AUC, #selected genes 1404/1710, Fset choice) — the novel method lives only in the gone repo; it is a stochastic metaheuristic (Grey-Wolf + Simulated Annealing) whose exact result is not recoverable without the authors' code and seeds. Not attempted; recorded as repo_gone.
- 35 "superior genes", named biomarkers (TOP2A, EZH2, ...), drug-target / enrichment / PPI downstream — all derive from the classifier output and/or external manual curation. Out of scope.
- Exact post-filter gene counts (10,629 / 11,731): depend on under-specified "unexpressed-probe removal"; treated as secondary (reported, not graded hard).
Reproduction strategy (80/20)
Reproduce the clearly-specified limma DEG counts (the low-hanging, deterministic pipeline output) on the public CEL data; do NOT chase the stochastic classifier. Partial reproduction is the expected, valid outcome.
Assessments & scoring basis
Each contributor’s verdict, the per-question basis, and the auditable, itemised worksheet behind it.
Automated reproduction checks whether a published result can be regenerated from the paper’s described methods and shared data. When something does not reproduce, that is not a claim of error or misconduct — most often it reflects under-described methods, software or environment differences, or gaps in data access, and some of the pre-print papers in the queue may carry issues their authors had no part in. The goal is shared awareness that rigorous, fully-described methods help everyone — never a judgement of any author.
Are you an author? We would genuinely like to hear from you — to clarify the record, add data or code, re-run the pipeline after an accession update, and publish your response right next to the assessment. Everything here is open and auditable.
🚩 Report an error in this record
Spotted something wrong — a verdict you’d contest, a data or value error, or a private detail that slipped through? Tell us, with a short justification. Authors and readers are equally welcome to write in; we review every report.
Prefer email, or the form below not working? Contact us at support@doesitreproduce.com.
Reproduction footprint
claude-opus-4-8Measured resources invested to assess this paper — sanitised (machine class only, no job ids/paths). Compute = HPC accounting (SLURM); tokens = the AI agent's session.